Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dedicated

- PMLiVE

Rebooting the innovation engine

How can the industry transform the efficacy of its R&D teams so they can do more with less?

- PMLiVE

GSK’s personalised cancer drug Tafinlar set for European approval

Regulatory advisors recommend the melanoma drug be licensed

- PMLiVE

Onyx rejects $10bn takeover bid from Amgen

Says offer is too low, but doesn't rule out a deal

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

- PMLiVE

Fresenius sells biotech business

Germany company's biotechnology arm picked up by Neopharm owners

- PMLiVE

Edward Hodgkin elected chair of UK biotech association

He will take up his new role at the BIA in October

mHealth: patients open to app prescriptions

Study suggests patients want to use technology to self-manage

KKR acquires clinical trials firm PRA International

Represents the second healthcare investment by the group in the last 12 months

Parexel adds flexibility to its clinical research offering

Also expands post marketing surveillances services in Japan

- PMLiVE

Baxter gets OK for BeneFix competitor in US

Rixubis becomes first new drug in its class in more than 15 years

- PMLiVE

GSK’s muscular dystrophy drug ‘a breakthrough’ says FDA

The antisense oligonucleotide is being developed by GlaxoSmithKline and Prosensa

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links